Ceryvyn Therapeutics Limited is a clinical-stage biopharmaceutical company researches and develops therapeutic products based on targeting vascular endothelial growth factors C, D and R3 principally in Australia and the United States. The company's pipeline includes Sozinibercept. Ceryvyn Therapeutics Limited, formerly known as Opthea Limited, is headquartered in Melbourne, Australia.
| Revenue (Most Recent Fiscal Year) | $0.03M |
| Net Income (Most Recent Fiscal Year) | $-162.79M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | -- |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | -- |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -- |
| Net Margin (Trailing 12 Months) | -- |
| Return on Equity (Trailing 12 Months) | -- |
| Return on Assets (Trailing 12 Months) | -- |
| Current Ratio (Most Recent Fiscal Quarter) | -- |
| Quick Ratio (Most Recent Fiscal Quarter) | -- |
| Debt to Common Equity (Most Recent Fiscal Quarter) | -- |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $-1.31 |
| Earnings per Share (Most Recent Fiscal Quarter) | -- |
| Earnings per Share (Most Recent Fiscal Year) | -- |
| Diluted Earnings per Share (Trailing 12 Months) | -- |
| Exchange | -- |
| Sector | -- |
| Industry | -- |
| Common Shares Outstanding | 171.00M |
| Free Float | 165.53M |
| Market Capitalization | $3.97M |
| Average Volume (Last 20 Days) | 5777.80 |
| Beta (Past 60 Months) | 1.48 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 3.20% |
| Percentage Held By Institutions (Latest 13F Reports) | 55.95% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |